This article is more than 5 years old. Information may no longer be current.

Re-treatment with sofosbuvir, interferon effective in HCV genotype 2 or 3

Issue: June 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Twelve weeks of re-treatment with a regimen that included sofosbuvir, pegylated interferon and ribavirin was effective in patients with genotype 2 or 3 hepatitis C who failed prior therapy with sofosbuvir and ribavirin, according to data presented here at Digestive Disease Week.

“A 24-week interferon-free regimen of sofosbuvir and ribavirin was also found safe and well-tolerated among these patients,” Lisa M. Nyberg, MD, of Kaiser Permanente in San Diego, said during her presentation. “The 12-week regimen containing interferon had higher overall rates of [sustained virologic response] and was more effective in patients with cirrhosis, but the 24-week interferon-free regimen offers a re-treatment option for those ineligible to receive interferon.”

The open-label trial included patients with genotype 2 or 3 HCV who failed treatment on the FISSION, POSITRON or FUSION trials of sofosbuvir (Sovaldi, Gilead). The patients were offered re-treatment with sofosbuvir, pegylated interferon and ribavirin for 12 weeks or sofosbuvir and ribavirin for 24 weeks. The study included patients with compensated cirrhosis.

The 12-week treatment arm had 34 patients, and sustained virologic response for 12 weeks (SVR12) data were available for 26. The 24-week treatment arm included 73 patients, 40 of whom had SVR12 data available. The SVR12 rate for the 12-week treatment was 92% vs. 63% for the 24-week treatment.

Among the patients with data available, six were genotype 2 and 60 were genotype 3. Going by genotype, the SVR12 rates for genotype 2 were 100% for 12-week treatment and 50% for 24-week treatment. For genotype 3, the SVR12 rates were 91% for the 12-week treatment and 63% for the 24-week treatment. There were 23 patients with cirrhosis, and the SVR12 rates for those patients were 88% for the 12-week treatment and 47% for the 24-week treatment.

For more information:

Nyberg L. #239. Presented at: Digestive Disease Week 2014; May 3-6, 2014; Chicago.

Disclosure: The researchers report numerous disclosures.